ArticlePrzeglad gastroenterologiczny2022
The effectiveness of microencapsulated sodium butyrate at reducing symptoms in patients with irritable bowel syndrome.
Article in Przeglad gastroenterologiczny, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 25 citations in OpenAlex.
- Efficacy of sodium butyrate in improving nonalcoholic fatty liver disease: A meta-analysis of preclinical studies.Medicine · 2025Pooled it
- Effect of microencapsulated sodium butyrate on abdominal symptoms and carbohydrate metabolism in patients with type 2 diabetes: a randomized placebo-controlled trial.Scientific reports · 2026Trial
- Efficacy of Microencapsulated Sodium Butyrate as Add-On Therapy in Inducing Remission in Patients with Mild-To-Moderate Ulcerative Colitis: Results From a Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study.Medical science monitor : international medical journal of experimental and clinical research · 2025Trial
- Possible Role of Butyric Acid in Long-Term Symptom Relief in Irritable Bowel Syndrome Patients Following Fecal Microbiota Transplantation.Neurogastroenterology and motility · 2025Trial
- Calcium butyrate efficacy in pediatric irritable bowel syndrome: Randomized placebo-controlled multiomics-based clinical trial.Journal of pediatric gastroenterology and nutrition · 2025Trial
- The Cost of the Cure: Antibiotic Exposure as a Risk Factor for Irritable Bowel Syndrome.Antibiotics (Basel, Switzerland) · 2026Review
- Use of Sodium Butyrate and Its Microencapsulated Forms in Intestinal Diseases-Current Clinical Approach.Digestive diseases and sciences · 2026Review
- Dietary tributyrin supplementation in Parkinson's disease: An open-label target engagement study.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Article
- Article
- Microencapsulated Sodium Butyrate in the Prevention of Acute Radiotherapy Proctitis: Single-Center Prospective Study.Journal of clinical medicine · 2025Article
- Microencapsulated Propionate and Butyrate Improved Energy Balance and Gut Microbiota Composition in Diet-Induced Obese Rats.Nutrients · 2025Article
- Clinical Efficacy of Sodium Butyrate in Managing Pediatric Inflammatory Bowel Disease.Life (Basel, Switzerland) · 2025Article
- Review
- The gut-brain axis and pain signalling mechanisms in the gastrointestinal tract.Nature reviews. Gastroenterology & hepatology · 2025Review
- Exploring Gut Microbiota Imbalance in Irritable Bowel Syndrome: Potential Therapeutic Effects of Probiotics and Their Metabolites.Nutrients · 2024Review
- Efficacy and Safety of a Mixture of Microencapsulated Sodium Butyrate, Probiotics, and Short Chain Fructooligosaccharides in Patients with Irritable Bowel Syndrome-A Randomized, Double-Blind, Placebo-Controlled Study.Journal of clinical medicine · 2024Article
- A Comprehensive Overview of Postbiotics with a Special Focus on Discovery Techniques and Clinical Applications.Foods (Basel, Switzerland) · 2024Review
- Harnessing and delivering microbial metabolites as therapeutics via advanced pharmaceutical approaches.Pharmacology & therapeutics · 2024Review
- Butyric acid and prospects for creation of new medicines based on its derivatives: a literature review.Journal of veterinary science · 2024Review
- The role and therapeutic effectiveness ofPrzeglad gastroenterologiczny · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: The aim of the study was to assess the effectiveness of a patented preparation of sodium butyrate in the triglyceride matrix at reducing clinical symptoms and improving quality of life in patients with irritable bowel syndrome (IBS). Material and methods: In this prospective multicenter clinical trial, we observed a total of 3000 non-hospitalized patients with confirmed IBS who were treated with sodium butyrate in a triglyceride matrix at a dosage of 150 mg twice a day for 12 weeks. The primary outcome was to evaluate the efficacy of sodium butyrate at reducing the severity of clinical symptoms and improving quality of life in patients with IBS. Results: A total of 2990 complete surveys were collected. A statistically significant improvement in severity of abdominal pain was noticed ( Conclusions: Sodium butyrate in the triglyceride matrix, as a postbiotic substance, may be effective in relieving the symptoms of IBS by modifying the intestinal microbiota.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.